1. Home
  2. LCFY vs LEXX Comparison

LCFY vs LEXX Comparison

Compare LCFY & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$2.47

Market Cap

8.3M

Sector

N/A

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

N/A

Current Price

$3.42

Market Cap

8.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LCFY
LEXX
Founded
2009
2004
Country
Australia
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
8.7M
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
LCFY
LEXX
Price
$2.47
$3.42
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
★ $1.50
AVG Volume (30 Days)
6.4K
★ 123.0K
Earning Date
05-12-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $705,923.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 52.05
52 Week Low
$2.10
$0.35
52 Week High
$7.67
$14.37

Technical Indicators

Market Signals
Indicator
LCFY
LEXX
Relative Strength Index (RSI) 54.81 36.48
Support Level $2.50 $0.57
Resistance Level $2.73 $12.89
Average True Range (ATR) 0.16 1.15
MACD 0.03 -0.44
Stochastic Oscillator 68.64 7.18

Price Performance

Historical Comparison
LCFY
LEXX

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: